IQVIA

ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension

Retrieved on: 
星期二, 四月 9, 2024
IQVIA, ANI, RLD, Pharmaceutical industry

BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®.

Key Points: 
  • BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®.
  • "The launch of Baclofen Oral Suspension represents another entry for ANI into a rapidly growing limited competition market.
  • We are proud of our ability to recognize the market need and provide our customers with the best suited packing configurations to match their requirements in a timely manner,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
  • U.S. annual sales for Baclofen Oral Suspension total approximately $39 million, according to IQVIA data.

Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Retrieved on: 
星期一, 四月 1, 2024
Cream, Psoriasis, Abbreviated New Drug Application, NESS, Partnership, District court, Patient, Nevoid basal-cell carcinoma syndrome, Dermatology, Patent, IQVIA, FDA, Sol–gel process, Food, Generic drug

On March 26, 2024, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”) initiated a patent infringement action in the U.S. District Court for the District of New Jersey regarding the Padagis Roflumilast Cream, 0.3% ANDA.

Key Points: 
  • On March 26, 2024, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”) initiated a patent infringement action in the U.S. District Court for the District of New Jersey regarding the Padagis Roflumilast Cream, 0.3% ANDA.
  • Annual market sales for Zoryve Cream, 0.3% were approximately $95 million in the 12 months ended in January 2024, as measured by IQVIA.
  • Should its ANDA for Roflumilast Cream, 0.3% be approved by the FDA, Padagis believes that its product may be entitled to 180 days of generic market exclusivity.
  • Submissions such as Padagis’s Roflumilast Cream, 0.3% ANDA demonstrate the historic value of Sol-Gel’s partnership with Padagis.

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

Retrieved on: 
星期三, 三月 13, 2024
Orphan drug, Growth, NESS, Nevoid basal-cell carcinoma syndrome, Disease, Patient, Research, European Medical Association, NDA, Acquisition, Prescription, EMA, Dermatology, Clinical trial, IQVIA, BCC, FDA, Sol–gel process, Carcinoma, Food, Pharmaceutical industry

On November 30, 2023, Sol-Gel announced that it had begun Phase 3 testing of SGT-610 for Gorlin syndrome, with the first patient screened.

Key Points: 
  • On November 30, 2023, Sol-Gel announced that it had begun Phase 3 testing of SGT-610 for Gorlin syndrome, with the first patient screened.
  • In addition, TWYNEO increased its broad commercial formulary coverage, with over 6 million additional lives covered between December 2022 and December 2023 per MMIT Analytics.
  • Based on Sol-Gel's financing and adoption of cost-saving measures during 2023, the company continues to maintain its cash runway into the second half of 2025.
  • The decrease in revenues in 2023 resulted mainly from the milestone payment from Galderma related to the FDA approval of Epsolay in 2022.

Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech

Retrieved on: 
星期二, 四月 2, 2024
Other Health, Research, General Health, Oncology, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Health, Partner (business rank), France Biotech, Patient, Cancer, LEEM, Imagination, Creativity, Merck Group, IQVIA, Multimedia, Pharma, Pharmaceutical industry

Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech .

Key Points: 
  • Brenus Pharma announces its distinction as the "Biotech of the year" received at the annual HealthTech Awards ceremony organized by France Biotech .
  • The ceremony took place on Monday, March 25th in Paris, gathering key players in the French health innovation ecosystem.
  • (France Biotech Press Release)
    This award testifies to the relevance of Brenus Pharma's mission: to restore the ability of cancer patients to fight resistant tumor cells and avoid relapses like never before.
  • Finally, congratulations to all the winning startups, nominees, and others who thrive and provide daily efforts for the health of patients."

Ephicacy Bolsters Leadership Team with Four New Hires

Retrieved on: 
星期三, 三月 27, 2024
Technology, Consulting, Health Technology, Professional Services, Biotechnology, Data Analytics, Pharmaceutical, Health, Data Management, Outsourcing Business, Financial management, ChromeOS, Growth, CFO, Cytel, Biostatistics, Head, Contract research organization, Genpact, FP&A, Accenture, IQVIA, FP, Amgen, Data management

Ephicacy Consulting Group, Inc., (“Ephicacy”), a leading biometrics Contract Research Organization (“CRO”) and global provider of statistical programming, biostatistics, data management and real-world evidence analytics services, today announced four senior leadership appointments that further position the company for continued growth.

Key Points: 
  • Ephicacy Consulting Group, Inc., (“Ephicacy”), a leading biometrics Contract Research Organization (“CRO”) and global provider of statistical programming, biostatistics, data management and real-world evidence analytics services, today announced four senior leadership appointments that further position the company for continued growth.
  • Jim Baker as Chief Operating Officer, to oversee operations across client engagement and business development for the global company.
  • Jim brings over 35 years of experience leading bioanalytical teams at CROs and pharmaceutical companies, including at Cytel, Takeda and Amgen.
  • “I look forward to working alongside the talented team to build on this momentum, drawing on my experience helping CROs expand and scale at important moments in their lifecycle.”

USA Patient Registry Software Market Outlook to 2028, Featuring IQVIA, Optum (UnitedHealth Group), Phytel, Dacima Software, FIGmd, Syapse and Pharos Innovations - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 19, 2024
Oncology, Research, Software, University, Infectious Diseases, Education, Hospitals, Health Technology, Genetics, Health Insurance, Data Management, Science, Technology, Clinical Trials, Biotechnology, FDA, Insurance, Health, Professional Services, IOT (Internet of Things), Data Analytics, White House, Federal Government, Practice Management, Managed Care, Other Health, Public Policy, Government, Pharmaceutical, Other Science, Pancreatic disease, Consolidated, Patient, Conditional sentence, Optum, Health information management, Food and Drug Administration, Geography, NPF, RWE, Internet of things, Openclinica, DNA, Policy, Electronic health record, NIH, City, Privacy, CMS, Food, Organization, Prevalence, Federation, Internet, Cancer, Drug development, IQVIA, Evidence-based medicine, RDCRN, Type, Data science, Caregiver, Public health surveillance, Government agency, Registry, EHR, CDC, National Institutes of Health, Bangladesh Technical Education Board, Medicare, Collection, Medical device

The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.

Key Points: 
  • The patient registry market in the US involves the collection, management & analysis of data related to patients with specific medical conditions & diseases.
  • Patient registry software could facilitate data sharing and analysis among these entities, leading to increased adoption
    The patient registry software market in the USA is a part of the broader healthcare information technology sector.
  • Key players in the USA patient registry software market includes IQVIA, Dacima Software, OpenClinica, FIGmd, Dendrite Clinical Systems and various universities conducting medical clinical studies.
  • As technology & data science continue to evolve, the patient registry software market is likely to incorporate more advanced analytics techniques.

Orsini Announcement: Orsini Specialty Pharmacy Welcomes Two Executive Leadership Hires

Retrieved on: 
星期四, 四月 4, 2024
Haddock, Growth, CFO, Eisai, Patient, ELK, Pharmacy, University, Senior, Express Scripts, IQVIA, Economics, Management

ELK GROVE VILLAGE, III., April 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy is pleased to announce that it has welcomed Victor Haddock as its new Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management.

Key Points: 
  • ELK GROVE VILLAGE, III., April 4, 2024 /PRNewswire/ -- Orsini Specialty Pharmacy is pleased to announce that it has welcomed Victor Haddock as its new Chief Financial Officer and Lynda Parker as Executive Vice President of Trade Relations and Account Management.
  • Orsini Specialty Pharmacy welcomes Victor Haddock and Lynda Parker to Executive Leadership Team.
  • Haddock has over 25 years of financial leadership experience in the healthcare sector, with a demonstrated ability to lead business strategies, implement change and build successful teams.
  • He most recently served as CFO of Triple-S Management in Puerto Rico, and he has held leadership positions at MagellanRx and Express Scripts.

Patient Registry Software Market Projected to Reach $4.44 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
星期四, 四月 4, 2024
Oracle Corporation, IBM, Growth, Intelligence, Conditional sentence, USAID, Research, IQVIA, Digital health, Health information exchange, Health, Safety, EHR, Disease, Trial of the century, Digital technology, Collection, Table, Medical device

The healthcare industry is witnessing a transformation by adopting patient registry software, a dynamic tool designed to aggregate, manage, and analyze patient data across various medical specialties.

Key Points: 
  • The healthcare industry is witnessing a transformation by adopting patient registry software, a dynamic tool designed to aggregate, manage, and analyze patient data across various medical specialties.
  • Africa is embracing the potential of patient registry software, driven by a commitment to addressing chronic diseases and enhancing healthcare quality.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Patient Registry Software Market.
  • "Dive into the Patient Registry Software Market Landscape: Explore 191 Pages of Insights, 748 Tables, and 28 Figures"

Patient Registry Software Market Projected to Reach $4.44 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
星期四, 四月 4, 2024
Oracle Corporation, IBM, Growth, Intelligence, Conditional sentence, USAID, Research, IQVIA, Digital health, Health information exchange, Health, Safety, EHR, Disease, Trial of the century, Digital technology, Collection, Table, Medical device

The healthcare industry is witnessing a transformation by adopting patient registry software, a dynamic tool designed to aggregate, manage, and analyze patient data across various medical specialties.

Key Points: 
  • The healthcare industry is witnessing a transformation by adopting patient registry software, a dynamic tool designed to aggregate, manage, and analyze patient data across various medical specialties.
  • Africa is embracing the potential of patient registry software, driven by a commitment to addressing chronic diseases and enhancing healthcare quality.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Patient Registry Software Market.
  • "Dive into the Patient Registry Software Market Landscape: Explore 191 Pages of Insights, 748 Tables, and 28 Figures"

Healthcare Analytics Market Size to Grow by USD 66.54 billion from 2024 to 2028, Market growth at 24.79% CAGR expected during the forecast period, Technavio

Retrieved on: 
星期四, 三月 14, 2024
Komodo, Cloud, Conditional sentence, Informatics, Corp, Component, Health, UnitedHealth Group, Epidemic, IQVIA, Health care, Artificial intelligence, Telehealth, Health information management, USD, Oracle Corporation, Risk, Policy, Cerner, Electronic health record, Information management, SAS Institute, Financial management, Automation, Documentation, Health information exchange, Risk management, Intelligence, Data mining, AI, Veeva Systems, Machine learning, Service, IBM, Mining, Growth, Big data, McKesson Corporation, Health informatics, EHR, Hardware, Retail

The report provides actionable insights and estimates the contribution of all regions to the growth of the global healthcare analytics market.

Key Points: 
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global healthcare analytics market.
  • The Healthcare Analytics Market is experiencing significant growth driven by advancements in healthcare data analytics, which encompass clinical, predictive, prescriptive, and descriptive analytics.
  • The Healthcare Analytics Market is witnessing substantial growth driven by advancements in healthcare data analytics, encompassing clinical, predictive, prescriptive, and descriptive analytics.
  • Emerging technologies drive market opportunities amidst challenges, positioning the healthcare analytics market for substantial growth and dynamic evolution.